>

Kenneth Frazier - Merck Chairman

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>MRK</div>
MRK -- USA Stock  

Earning Report: 28th of April 2020  

  Chairman
Mr. Kenneth C. Frazier is Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company and Merck Sharp Dohme Corporationration . Mr. Frazier also served as Executive Vice President and General Counsel of Merck Sharp Dohme Corporationration . Director, Exxon Mobil Corporationrationration since 2009 and Pharmaceutical Research and Manufacturers of America since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association. Mr. Frazier has broad managerial and operational expertise and deep institutional knowledge, as well as a track record of achievement, integrity and sound judgment demonstrated prior to, and during his long tenure with Merck. In addition, his role as the Chair of the Board Affairs Committee of Exxon Mobil Corporationrationration has provided him with important experience on governance issues facing public companies.
Age: 63  Chairman Since 2011      
908 735-1500  www.merck.com
Frazier also served as Executive Vice President and General Counsel of Merck Sharp & Dohme Corporationrationration . Director, Exxon Mobil Corporationrationrationration since 2009 and Pharmaceutical Research and Manufacturers of America since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA; Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association.

Kenneth Frazier Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.13 % which means that on every $100 spent on asset it made $0.13 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.39 % implying that it generated $0.39 on every 100 dollars invested.
The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Joerg ReinhardtNovartis AG
2013
Daniel VasellaNovartis AG
N/A
Paulus StoffelsJohnson Johnson
2018
Ulrich LehnerNovartis AG
2006
Thibaut MongonJohnson Johnson
2018
Alex KrauerNovartis AG
N/A
Joaquin DuatoJohnson Johnson
2018
Jennifer TaubertJohnson Johnson
2018
Ashley McEvoyJohnson Johnson
2018
Sandra PetersonJohnson Johnson
2017
Jorge MesquitaJohnson Johnson
2016
Enrico VanniNovartis AG
2013
Giovanni CaforioBristol Myers Squibb Company
2017
Moncef SlaouiGlaxoSmithKline PLC
2014
Brenton SaundersAllergan Plc
2016
Alex GorskyJohnson Johnson
2012
John LechleiterEli Lilly And Company
2016
Leif JohanssonAstrazeneca PLC
2012
Lamberto AndreottiBristol Myers Squibb Company
2015
Daniel ODayGilead Sciences
2019
Paul BisaroAllergan Plc
2016

Company Summary

It operates through Pharmaceutical and Animal Health segments. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 71000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States and employs 71,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Leadership Team

Thomas Glocer, Independent DirectorView
Craig Thompson, Independent DirectorView
Jennifer Zachary, Executive Vice President, General CounselView
Rochelle Lazarus, Independent DirectorView
Christine Seidman, DirectorView
Michael Rosenblatt, Executive Vice President Chief Medical OfficerView
Wendell Weeks, Independent DirectorView
Michael Holston, Executive Vice President Chief Ethics and Compliance OfficerView
Kathy Warden, DirectorView
Paul Rothman, Independent DirectorView
Mary Coe, Independent DirectorView
Adele Ambrose, Senior Vice President Chief Communications OfficerView
Joseph Romanelli, IR Contact OfficerView
Mirian GraddickWeir, Executive Vice President - Human ResourcesView
Peter Wendell, Independent DirectorView
John Noseworthy, Independent DirectorView
Leslie Brun, Lead Independent DirectorView
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population HealthView
Inge Thulin, Independent DirectorView
Pamela Craig, Independent DirectorView
Patricia Russo, Independent DirectorView
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing DivisionView
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global ControllerView
Robert Davis, Executive Vice President, Global Services, Chief Financial OfficerView
Robert Kidder, Independent DirectorView
Thomas Cech, Independent DirectorView
Michael Nally, Executive Vice President, Chief Marketing OfficerView
Clark Golestani, CIO and Executive VPView
William Harrison, Lead Independent DirectorView
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research LaboratoriesView
Ashley Watson, Senior Vice President Chief Ethics and Compliance OfficerView
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human ResourcesView
Jim Scholefield, Executive Vice President, Chief Information and Digital OfficerView
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing DivisionView
Adam Schechter, President of Global Human Health and Executive VPView
Carlos Represas, Independent DirectorView
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal HealthView
Kenneth Frazier, Chairman of the Board, President, Chief Executive OfficerView
Frank Clyburn, Executive Vice President, Chief Commercial OfficerView

Stock Performance Indicators

Current Sentiment - MRK

Merck Investor Sentiment

Predominant part of Macroaxis users are now bullish on Merck Company. What is your trading attitude regarding investing in Merck Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page